Skip to main content
Laekna, Inc. logo

Laekna, Inc. — Investor Relations & Filings

Ticker · 2105 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 130 across all filing types
Latest filing 2026-04-15 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2105

About Laekna, Inc.

http://www.laekna.com

Laekna, Inc. is a science-driven, clinical-stage biotechnology company founded in 2016. The company specializes in the discovery, development, and commercialization of innovative therapies, particularly focusing on immunology treatments. Laekna's core mission is to bring novel therapeutics to patients suffering from cancer (oncology), metabolic diseases, and liver fibrosis, addressing significant unmet medical needs across these therapeutic areas.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION POSITIVE TOPLINE RESULTS PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) MET PRIMARY ENDPOINT OF PFS DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANI
Regulatory Filings Classification · 1% confidence The document is an announcement made under Rule 13.09 of the Hong Kong Listing Rules, disclosing ‘inside information’ regarding Phase III clinical trial topline results for a pharmaceutical product. It is not a financial report (quarterly, annual, or earnings release), nor a management or investor presentation, nor related to corporate actions like dividends, share issues, or M&A. It is a required regulatory announcement of material information by a listed issuer. As such, it falls into the fallback category of general regulatory filings.
2026-04-15 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 1% confidence The document is a full Environmental, Social and Governance Report (2025 ESG Report) for Laekna, Inc. It details ESG strategy, performance highlights, governance structures, environmental metrics, social initiatives, and related disclosures. This aligns precisely with the description for "Environmental & Social Information" (Code: SR).
2026-04-13 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Exchange showing movements in authorised share capital, issued shares, share options, etc., under Chapter 19B of the Listing Rules. It is not an annual, interim, earnings release, proxy, director dealing, dividend notice, or other specific category. It is a regulatory filing under HKEX listing requirements, and does not announce a standalone report or a specific corporate action beyond the standard monthly return. Therefore it falls into the fallback category “Regulatory Filings (RNS).”
2026-04-02 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Annual Report Classification · 1% confidence The document is an 'Annual Results Announcement' for Laekna, Inc. for the year ended December 31, 2025. It contains detailed business highlights, clinical trial progress, and consolidated financial statements (Profit or Loss, etc.). While it is an announcement, it provides the substantive financial data and performance analysis for the full fiscal year, which aligns with the definition of an Annual Report (10-K) in the context of HKEX-listed companies where the 'Annual Results Announcement' serves as the primary disclosure of annual financial performance. FY 2025
2026-03-18 English
VOLUNTARY ANNOUNCEMENT POSITIVE TOPLINE RESULTS FROM U.S. PHASE I SAD STUDY OF LAE102 SHOWED ENCOURAGING TRENDS TOWARD LEAN MASS INCREASE AND FAT MASS REDUCTION
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Laekna, Inc. regarding the positive topline results of a Phase I clinical trial for their drug candidate LAE102. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding business and clinical trial updates, it falls under the RNS (Regulatory Filings) category.
2026-03-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.